Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra is a leading thrombectomy company with innovative technology and a strong portfolio of products, including the recently launched THUNDERBOLT, which addresses a critical need in stroke care. The company's ability to continuously innovate and its low sales force turnover supports our expectation of double-digit revenue growth in the foreseeable future. We have a price target of $374 based on a DCF and EV-to-sales multiple, reflecting potential acquisition by Boston Scientific which we see as the most likely acquirer. The acquisition price reflects market expectations for the deal to go through, which is consistent with our expectation.

Bears say

Penumbra is facing strong competition in the neurovascular market from larger companies, and their premium pricing strategy may be difficult to sustain without near-perfect success rates. With the potential for a higher bid already priced in, any failure to change the treatment paradigm could negatively impact their growth potential.

Penumbra (PEN) has been analyzed by 15 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Hold based on their latest research and market trends.

According to 15 analysts, Penumbra (PEN) has a Hold consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $358.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $358.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.